M. Pufulete

First name
M.
Last name
Pufulete
Harris, J., Pouwels, K. B., Johnson, T., Sterne, J., Pithara, C., Mahadevan, K., et al. (2023). Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies. Health Technol Assess, 27, 1-257. http://doi.org/10.3310/mnjy9014
Pufulete, M., Harris, J., Pouwels, K., Reeves, B. C., Lasserson, D., Loke, Y. K., et al. (2022). Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England. Open Heart, 9. http://doi.org/10.1136/openhrt-2022-001999
Mohiuddin, S., Reeves, B., Pufulete, M., Maishman, R., Dayer, M., Macleod, J., et al. (2016). Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. BMJ Open. http://doi.org/10.1136/bmjopen-2016-014010
Hollingworth, W., Biswas, M., Maishman, R. L., Dayer, M. J., McDonagh, T., Purdy, S., et al. (2016). The healthcare costs of heart failure during the last five years of life: A retrospective cohort study. Int J Cardiol. http://doi.org/10.1016/j.ijcard.2016.09.021
Pufulete, M., Maishman, R., Dabner, L., Mohiuddin, S., Hollingworth, W., Rogers, C. A., et al. (2017). Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. Health Technol Assess. http://doi.org/10.3310/hta21400